China Medical GatewayLoading your healthcare gateway…

Sheng Xi Nan

Sheng Xi Nan — Chief Physician — Urologic Oncology — Peking University Cancer Hospital

Specialties

Mainly engaged in multidisciplinary comprehensive treatment and translational research of urological tumors such as renal cancer and bladder cancer, as well as malignant melanoma, with particularly rich clinical experience accumulated in advanced renal cancer, urothelial carcinoma, and mucosal malignant melanoma.

Professional Experience

Chief Physician, Professor, and Doctoral Supervisor, currently serving as the Deputy Director of the Department of Renal Cancer and Melanoma at Peking University Cancer Hospital. He mainly engages in multidisciplinary comprehensive treatment and translational research of urinary tumors such as renal cancer and bladder cancer, as well as malignant melanoma, particularly accumulated rich clinical experience in advanced renal cancer, urothelial carcinoma, and mucosal malignant melanoma. As a specific project executor, he has completed multiple clinical studies on urinary tumors, especially advanced renal cancer, urothelial carcinoma, and melanoma. His related work has been recognized by peers both domestically and internationally and has been incorporated into the NCCN Kidney Cancer Guidelines, the UK Head and Neck Mucosal Melanoma Guidelines, as well as the CSCO Kidney Cancer, Urothelial Carcinoma, and Melanoma Diagnosis and Treatment Guidelines. As a lead author, he has participated in drafting multiple versions of the CSCO guidelines for kidney cancer, urothelial carcinoma, and prostate cancer, contributing to the standardized diagnosis and treatment of urinary tumors in China, and has been recognized as an Outstanding Young Scientist in Chinese Urologic Oncology.

Professional Roles

Member of the Bladder Cancer Quality Control Expert Committee of the National Cancer Quality Control Center, Director of the Chinese Society of Clinical Oncology (CSCO), Executive Director of the Youth Council of the Chinese Anti-Cancer Association, Standing Member of the CSCO Urothelial Cancer Expert Committee, Standing Member and Secretary-General of the CSCO Kidney Cancer Expert Committee, Standing Member of the Urological Tumor Committee of the Chinese Anti-Cancer Association, Deputy Leader of the Rare Type Kidney Cancer Collaboration Group of the Urological Tumor Committee of the Chinese Anti-Cancer Association, Chairperson of the Youth Committee of the Urologic and Male Genitourinary Tumor Professional Committee of the Beijing Anti-Cancer Association, and Incoming Chairperson of the Urological Tumor Subcommittee of the Beijing Society for Cancer Prevention and Treatment.

Return to Home